News and Announcements
Oncosil Medical Group (ASX:OSL) Annual Update 2015; Shares Up Over 182%
- Published January 05, 2016 2:42PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
2015 Highlights:
- Share price up 182.35%
- Completed the granted Fast Track review by the European regulator Conformité Européenne
- International life sciences research group, Van Leeuwenhoeck Institute, initiated an analyst research coverage on the Company
- Multiple new Board Appointments
ABOUT ONCOSIL MEDICAL GROUP:
OncoSil™ is a patent protected proprietary medical device (class III) that creates a localised stream of beta radiation. The product is created by melting up to 5% phosphorous in liquid silicon in a furnace which is then shattered into small particles using sterile water. The resulting radioactive phosphorous (P32) produces radioactive beta particles that can be emitted for up to three months.
Patients with unresectable pancreatic cancer have few treatment options. The current standard of care is to provide intravenous chemotherapy, and in some cases external beam radiation. The OncoSil™ is intended to complement existing standard of care chemotherapy.